Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis

Recruiting Observational Study
Prostate Cancer Organoid
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Study type
Observational
Participants needed
35 (estimated)
Sponsor
Tianjin Medical University Second Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients with visceral metastasis of prostate cancer diagnosed clinically or pathologically; 2. Age ≥ 18 years old; 3. ECOG score ≤ 2 points or ECOG score 3-4 points due to tumor progression; 4. Normal liver and kidney function, serum transaminase ALT\<66 U/L, AST\<36 U/L, to…
Contacts

Haitao Wang, Ph.D

+86-022-88326385

peterrock2000@126.com

CONTACT

Jinhuan Wang, Ph.D

+86-022-88326610

wjhhappy2008@163.com

CONTACT